Rapport Therapeutics (RAPP) Files Form 144 for $1.2M Share Sale

Rhea-AI Filing Summary

Form 144 notice for Rapport Therapeutics, Inc. (RAPP) reports a proposed sale of 45,751 common shares through Morgan Stanley Smith Barney LLC on 09/17/2025 on NASDAQ with an aggregate market value of $1,198,218.69. The shares were acquired from the issuer under an RSA on 06/10/2024, and no securities were reported sold in the prior three months by the selling person. The filing includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer. This notice provides the broker, share count, acquisition details, planned sale date, and aggregate value as required under Rule 144.

Positive

• Full disclosure of broker, share count, aggregate market value, acquisition date, and planned sale date
• No securities sold in the prior three months reported for the selling person
• Seller attestation that they do not possess undisclosed material adverse information

Negative

• Insider proposes to sell 45,751 shares, representing an outflow of company-issued shares
• Aggregate market value of $1,198,218.69 will be transacted if sale occurs as proposed

Insights

Securities Analyst

TL;DR: Routine Rule 144 disclosure of insider plan to sell RSA shares; information is complete for compliance purposes.

The filing shows a proposed sale of 45,751 common shares with an aggregate market value of $1,198,218.69 to be executed through Morgan Stanley Smith Barney on NASDAQ. Acquisition details (RSA on 06/10/2024) are provided and the filer reports no sales in the past three months. From a securities compliance perspective, the notice contains the standard elements required by Rule 144: class of securities, broker, number of shares, aggregate value, outstanding shares count, acquisition date and nature, and planned sale date. There are no earnings or operational disclosures in this form to assess underlying business performance.

Corporate Governance Expert

TL;DR: A disclosed insider sale under Rule 144; disclosure aligns with governance transparency expectations.

The report documents an intended sale of equity awarded via RSA and provides the broker and timing details necessary for market transparency. The filer also affirms absence of undisclosed material adverse information, which is the standard attestation on Form 144. The filing does not indicate any clustered prior sales (it notes "Nothing to Report" for the past three months), which is relevant to assessing potential concentrated insider selling. No governance irregularities or procedural omissions are evident within the content provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	45751	1198218.69	36497920	09/17/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/10/2024	RSA	Issuer			45751	06/10/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by Rapport Therapeutics (RAPP) disclose?

The filing discloses a proposed sale of 45,751 common shares through Morgan Stanley Smith Barney LLC on 09/17/2025 on NASDAQ with an aggregate market value of $1,198,218.69.

How and when were the shares that are to be sold acquired?

The shares were acquired from the issuer under an RSA on 06/10/2024, per the filing.

Did the filer report any securities sold in the past three months?

No. The Form 144 states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Through which broker will the proposed sale be executed?

Morgan Stanley Smith Barney LLC is listed as the broker and the address provided is 1 New York Plaza, 8th Floor, New York, NY 10004.

Does the filing include any statement about undisclosed material information?

Yes. The person for whose account the securities are to be sold represents by signing the notice that they do not know any material adverse information about the issuer that has not been publicly disclosed.